Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirodenafil + rivastigmine
- Development stage
- Phase 2
- Lead developer
- AriBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AR1005 is a fixed-dose combination (FDC) drug candidate being developed by AriBio for the treatment of Lewy body disease (LBD), including dementia with Lewy bodies. The product combines mirodenafil (also known as AR1001), a selective phosphodiesterase 5 (PDE5) inhibitor, with rivastigmine, a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor that is a standard-of-care treatment for LBD. Mirodenafil is intended to enhance the nitric oxide (NO)/cGMP signaling pathway, promoting neuroprotection, synaptic plasticity, and improved cerebral blood flow, while rivastigmine addresses the cholinergic deficit characteristic of the disease. By combining these two mechanisms, AR1005 aims to provide synergistic improvements in cognitive function, behavioral psychological symptoms, and motor fluctuations. The drug is currently being evaluated in a Phase 2a clinical trial (NCT06537076) in patients with cognitive impairment due to Lewy body disease.
- Other names
- AR1001 + rivastigmine
02
Targets
PDE5 (Phosphodiesterase 5A)Acetylcholinesterase
Beyond the preview
Go deeper on mirodenafil + rivastigmine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirodenafil + rivastigmine.